FDA launches early probes on Sanofi, Takeda drugs
The agency is reviewing a possible interaction between Sanofi’s heart drug Multaq and the blood thinner Warfarin that could lead to an ‘increased anticoagulant effect’. Takeda’s diabetes drug
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.